Saturday, September 25, 2010 6:03:26 PM
September 24, 2010 8:06 AM EDT
Deutsche Bank maintains a 'Buy' on Amylin Pharmaceuticals (Nasdaq: AMLN), PT $27.
Deutsche analyst says, "Amylin is awaiting approval of its long-acting diabetes drug, Bydureon, which is a GLP-1 agonist. This class of drugs is used after oral therapy before insulin. Street controversy has focused not on IF Bydureon will be approved (Oct 22 is FDA PDUFA date), but how BIG peak sales will be. Our analysis suggests peak sales of Bydureon of $1.4B in '14 and $3B by '20 in the U.S. alone. We rate the stock a Buy because we believe Bydureon sales will be greater than street expectations."
"NY Times reported a potential sale of Amylin in ’09. We view Amylin as a possible acquisition candidate for a large pharma company with a diabetes sales force. Acquirer could extract significant SG&A and R&D synergies. Our M&A analysis indicates Lilly (NYSE: ELY) and Takeda make most sense with M&A value at $43-$44/share."
To see all the upgrades/downgrades on shares of AMLN, visit our Analyst Ratings page.
The 52-wk trading range is $11.01 - 24.21.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM